Meningococcal Vaccine Market Research Report from 2023 forecast to 2029, by Manufacturers, Regions, Type and Application

The global Meningococcal Vaccine market size was valued at USD 269.6 million in 2022 and is forecast to a readjusted size of USD 359.8 million by 2029 with a CAGR of 4.2% during review period.

Meningococcal vaccine refers to any of the vaccines used to prevent infection by Neisseria meningitides. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin.

Global Meningococcal Vaccine key players include GSK, SANOFI PASTEUR S.A, Norvatis, Crucell, Medimmune, etc. Global top five players hold a share about 80%. Europe is the largest market, with a share about 45%, followed by North America and China, having a total share about 40 percent. In terms of product, Polysaccharide Meningtitis AC is the largest segment, with a share about 95%. And in terms of application, the largest application is 6 Months-15Year, followed by over 3 Year, over 2 Year, over 3 Months.

This report is a detailed and comprehensive analysis for global Meningococcal Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

Global Meningococcal Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (10K Pcs), and average selling prices (USD/Pcs), 2018-2029
Global Meningococcal Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (10K Pcs), and average selling prices (USD/Pcs), 2018-2029
Global Meningococcal Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (10K Pcs), and average selling prices (USD/Pcs), 2018-2029
Global Meningococcal Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (10K Pcs), and ASP (USD/Pcs), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Meningococcal Vaccine
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace

This report profiles key players in the global Meningococcal Vaccine market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

   Novartis
   GSK
   Merck
   CSL
   Baxter
   JN International Medical Corporation
   Serum Institute of India
   Bio-Med
   China National Biotec Group
   Hualan Bio
   Walvax
   Zhifei

   Meningtits A
   Polysaccharide Meningtitis AC
   Meningitis ACYW

   6 Months-15Year
   over 3 Year
   over 2 Year
   over 3 Months

   North America (United States, Canada and Mexico)
   Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
   Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
   South America (Brazil, Argentina, Colombia, and Rest of South America)
   Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

What are the strengths of the Meningococcal Vaccine Market in 2025?

The Meningococcal Vaccine Market in 2025 benefits from growing awareness of meningitis and increased vaccination rates globally. Enhanced immunization programs, especially in developing countries, drive market growth. Additionally, improved vaccine efficacy and the expansion of combination vaccines contribute to the market's strength.

What are the weaknesses of the Meningococcal Vaccine Market in 2025?

A major weakness is the relatively high cost of vaccines, which can limit accessibility in low-income regions. There is also limited awareness in certain areas, particularly rural or underserved populations. Additionally, challenges in vaccine distribution and storage, particularly in tropical regions, remain obstacles to market growth.

What opportunities exist for the Meningococcal Vaccine Market in 2025?

There are significant opportunities in expanding vaccination programs in emerging markets, driven by government initiatives and international funding. The development of new and more affordable vaccines could broaden market access. Research into vaccine combinations and new meningococcal strains also presents a growing area of opportunity.

What threats could impact the Meningococcal Vaccine Market in 2025?

The primary threat to the market is the potential for vaccine hesitancy and misinformation, which could reduce uptake in certain populations. Additionally, political instability or public health crises in certain regions could disrupt vaccine distribution. Competition from other vaccine providers or substitutes could also pose a threat to market share.

What are the political factors influencing the Meningococcal Vaccine Market in 2025?

Government policies, including mandatory vaccination programs and public health initiatives, significantly influence the Meningococcal Vaccine Market. International cooperation and funding, especially for low-income countries, also play a key role in vaccine accessibility and distribution.

How do economic factors affect the Meningococcal Vaccine Market in 2025?

Economic conditions impact healthcare budgets and vaccine affordability. In economically developed regions, funding for vaccination programs is generally stable, whereas in lower-income countries, economic constraints can limit access to vaccines, slowing market growth.

What social factors influence the Meningococcal Vaccine Market in 2025?

Public awareness of meningitis and the importance of vaccination is crucial. Social factors like vaccine acceptance and hesitancy can significantly impact vaccination rates. Cultural beliefs and attitudes toward vaccination also vary across regions, influencing market dynamics.

How does technology impact the Meningococcal Vaccine Market in 2025?

Advances in vaccine development, such as improved formulations and combination vaccines, enhance efficacy and broaden market appeal. Technological innovations in cold chain management and distribution also help in overcoming logistical challenges, especially in remote areas.

What environmental factors affect the Meningococcal Vaccine Market in 2025?

Climate change can affect the spread of meningococcal disease, particularly in areas with rising temperatures. Environmental factors also influence vaccine storage and distribution, as certain vaccines require specific temperature controls, which can be a challenge in developing countries.

What legal factors shape the Meningococcal Vaccine Market in 2025?

Regulations surrounding vaccine approval, pricing, and distribution play a significant role in shaping the market. Legal requirements for vaccination, particularly in school settings or during international travel, can drive demand. Additionally, intellectual property laws around vaccine patents and production impact market competition.

Who are the suppliers in the Meningococcal Vaccine Market 2025?

Suppliers in this market include vaccine manufacturers, raw material providers (such as antigens and adjuvants), contract research organizations (CROs) for clinical trials, and distributors responsible for global and regional delivery.

What are the inputs in the Meningococcal Vaccine Market 2025?

The key inputs include research data for vaccine development, high-quality raw materials for production, skilled labor for manufacturing, technology for formulation, and regulatory approvals required for market entry.

What processes are involved in the Meningococcal Vaccine Market 2025?

Processes include vaccine research and development, manufacturing, clinical trials for efficacy and safety, regulatory approvals from health authorities, distribution through various channels, and public health vaccination programs.

Who are the customers in the Meningococcal Vaccine Market 2025?

The primary customers are government health agencies, hospitals, clinics, healthcare providers, international health organizations, and individuals, especially those in high-risk groups or travelers to meningitis-prone regions.

What are the outputs in the Meningococcal Vaccine Market 2025?

The outputs consist of fully developed, approved meningococcal vaccines, improved population health outcomes with reduced cases of meningococcal disease, and public health initiatives that increase global vaccination coverage.

What is the threat of new entrants in the Meningococcal Vaccine Market 2025?

The threat of new entrants is moderate. While the market offers growth opportunities, the high costs of research and development, regulatory hurdles, and the need for advanced manufacturing capabilities limit the number of new players.

What is the bargaining power of suppliers in the Meningococcal Vaccine Market 2025?

The bargaining power of suppliers is moderate. While raw materials and specialized production equipment are necessary for vaccine development, the presence of multiple suppliers and the critical role of government contracts helps balance their influence.

What is the bargaining power of buyers in the Meningococcal Vaccine Market 2025?

The bargaining power of buyers is relatively low. Buyers, primarily governments and large health organizations, often face limited options for vaccines and rely on regulatory-approved products, giving vaccine manufacturers more influence.

What is the threat of substitute products in the Meningococcal Vaccine Market 2025?

The threat of substitutes is low. While there are other preventive measures like antibiotics or treatments for meningitis, there are no direct substitutes for vaccines that provide long-term, widespread immunity against meningococcal disease.

What is the intensity of competitive rivalry in the Meningococcal Vaccine Market 2025?

The intensity of competitive rivalry is moderate. A few large pharmaceutical companies dominate the market, but competition remains fierce, especially with the ongoing development of newer and more effective vaccines to capture market share.

What are the key upstream factors in the Meningococcal Vaccine Market 2025?

The key upstream factors include the availability and cost of raw materials such as antigens, adjuvants, and excipients. Research and development investments, along with the availability of skilled labor for vaccine production, are also crucial in this stage.

How do regulatory requirements affect the upstream segment of the Meningococcal Vaccine Market?

Regulatory requirements significantly impact the upstream process, as vaccine development must meet strict standards for safety, efficacy, and manufacturing practices. Compliance with international and regional regulatory bodies is essential for ensuring the approval of vaccines.

What role do suppliers play in the upstream segment of the Meningococcal Vaccine Market?

Suppliers play a crucial role in providing high-quality raw materials, such as the biological agents needed for vaccine production, as well as specialized equipment for manufacturing. Their ability to meet quality standards and supply the required quantities is critical for timely production.

How does research and development impact the upstream segment of the Meningococcal Vaccine Market?

R&D is a major upstream factor, as it drives the innovation of new vaccines and improvements in existing formulations. Ongoing research into new strains of meningococcal bacteria and vaccine delivery methods will influence future vaccine production and market offerings.

What challenges are faced by the upstream segment of the Meningococcal Vaccine Market?

Challenges include ensuring the consistent supply of high-quality raw materials, navigating complex regulatory environments, and the high costs associated with vaccine development. Additionally, logistical issues related to maintaining vaccine stability, particularly in resource-poor settings, pose ongoing difficulties.

What are the key midstream activities in the Meningococcal Vaccine Market 2025?

Key midstream activities include the manufacturing process, quality control, and packaging of the vaccines. This phase also involves clinical trials to test vaccine efficacy and safety, as well as obtaining regulatory approvals for market launch.

How does manufacturing affect the midstream segment of the Meningococcal Vaccine Market?

Manufacturing is a critical element in the midstream segment. The ability to scale up production while maintaining high standards of quality control ensures that vaccines are safe, effective, and available in sufficient quantities to meet global demand.

What role do logistics and distribution play in the midstream segment of the Meningococcal Vaccine Market?

Logistics and distribution are vital to ensuring that vaccines are delivered efficiently to healthcare providers, governments, and organizations. Maintaining cold chain storage and distribution systems is crucial for the stability of the vaccine, especially in remote or developing regions.

How do clinical trials impact the midstream segment of the Meningococcal Vaccine Market?

Clinical trials directly impact the market by determining the safety and efficacy of vaccines. Successful trials lead to regulatory approvals, enabling vaccines to enter the market. However, delays in trials or failures in efficacy can hinder the progress of vaccines.

What challenges are faced in the midstream segment of the Meningococcal Vaccine Market?

Challenges in the midstream segment include ensuring manufacturing consistency, adhering to strict regulatory standards, managing cold chain logistics, and handling supply chain disruptions that can delay vaccine delivery to critical markets.

What are the key downstream activities in the Meningococcal Vaccine Market 2025?

Key downstream activities include the administration of the vaccine through healthcare providers, public health programs, and vaccination campaigns. This stage also involves post-vaccination monitoring and managing vaccine distribution to the final consumer.

How does market access impact the downstream segment of the Meningococcal Vaccine Market?

Market access is crucial in the downstream segment as it ensures that vaccines reach the target populations. This involves partnerships with governments, NGOs, and healthcare organizations to facilitate widespread distribution, especially in high-risk areas.

What role do healthcare providers play in the downstream segment of the Meningococcal Vaccine Market?

Healthcare providers play a significant role in educating the public, administering the vaccine, and monitoring patient outcomes. Their expertise and trustworthiness are vital for ensuring that vaccination programs are successful and that individuals receive the vaccine on time.

How does demand from high-risk populations affect the downstream segment of the Meningococcal Vaccine Market?

Demand from high-risk populations, such as infants, travelers, and individuals in meningitis-endemic regions, directly influences the downstream market. Increased awareness and targeted vaccination programs for these groups can lead to higher vaccine uptake.

What challenges are faced in the downstream segment of the Meningococcal Vaccine Market?

Challenges in the downstream segment include vaccine hesitancy, logistical difficulties in reaching remote or underserved populations, and ensuring vaccine affordability in low-income areas. Additionally, there may be challenges in managing post-vaccination adverse events and maintaining public confidence.

Chapter 1, to describe Meningococcal Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Meningococcal Vaccine, with price, sales, revenue and global market share of Meningococcal Vaccine from 2018 to 2023.
Chapter 3, the Meningococcal Vaccine competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Meningococcal Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Meningococcal Vaccine market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Meningococcal Vaccine.
Chapter 14 and 15, to describe Meningococcal Vaccine sales channel, distributors, customers, research findings and conclusion.

1 Market Overview

   1.1 Product Overview and Scope of Meningococcal Vaccine
   1.2 Market Estimation Caveats and Base Year
   1.3 Market Analysis by Type
       1.3.1 Overview: Global Meningococcal Vaccine Consumption Value by Type: 2018 Versus 2022 Versus 2029
       1.3.2 Meningtits A
       1.3.3 Polysaccharide Meningtitis AC
       1.3.4 Meningitis ACYW
   1.4 Market Analysis by Application
       1.4.1 Overview: Global Meningococcal Vaccine Consumption Value by Application: 2018 Versus 2022 Versus 2029
       1.4.2 6 Months-15Year
       1.4.3 over 3 Year
       1.4.4 over 2 Year
       1.4.5 over 3 Months
   1.5 Global Meningococcal Vaccine Market Size & Forecast
       1.5.1 Global Meningococcal Vaccine Consumption Value (2018 & 2022 & 2029)
       1.5.2 Global Meningococcal Vaccine Sales Quantity (2018-2029)
       1.5.3 Global Meningococcal Vaccine Average Price (2018-2029)

2 Manufacturers Profiles

   2.1 Novartis
       2.1.1 Novartis Details
       2.1.2 Novartis Major Business
       2.1.3 Novartis Meningococcal Vaccine Product and Services
       2.1.4 Novartis Meningococcal Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.1.5 Novartis Recent Developments/Updates
   2.2 GSK
       2.2.1 GSK Details
       2.2.2 GSK Major Business
       2.2.3 GSK Meningococcal Vaccine Product and Services
       2.2.4 GSK Meningococcal Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.2.5 GSK Recent Developments/Updates
   2.3 Merck
       2.3.1 Merck Details
       2.3.2 Merck Major Business
       2.3.3 Merck Meningococcal Vaccine Product and Services
       2.3.4 Merck Meningococcal Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.3.5 Merck Recent Developments/Updates
   2.4 CSL
       2.4.1 CSL Details
       2.4.2 CSL Major Business
       2.4.3 CSL Meningococcal Vaccine Product and Services
       2.4.4 CSL Meningococcal Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.4.5 CSL Recent Developments/Updates
   2.5 Baxter
       2.5.1 Baxter Details
       2.5.2 Baxter Major Business
       2.5.3 Baxter Meningococcal Vaccine Product and Services
       2.5.4 Baxter Meningococcal Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.5.5 Baxter Recent Developments/Updates
   2.6 JN International Medical Corporation
       2.6.1 JN International Medical Corporation Details
       2.6.2 JN International Medical Corporation Major Business
       2.6.3 JN International Medical Corporation Meningococcal Vaccine Product and Services
       2.6.4 JN International Medical Corporation Meningococcal Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.6.5 JN International Medical Corporation Recent Developments/Updates
   2.7 Serum Institute of India
       2.7.1 Serum Institute of India Details
       2.7.2 Serum Institute of India Major Business
       2.7.3 Serum Institute of India Meningococcal Vaccine Product and Services
       2.7.4 Serum Institute of India Meningococcal Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.7.5 Serum Institute of India Recent Developments/Updates
   2.8 Bio-Med
       2.8.1 Bio-Med Details
       2.8.2 Bio-Med Major Business
       2.8.3 Bio-Med Meningococcal Vaccine Product and Services
       2.8.4 Bio-Med Meningococcal Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.8.5 Bio-Med Recent Developments/Updates
   2.9 China National Biotec Group
       2.9.1 China National Biotec Group Details
       2.9.2 China National Biotec Group Major Business
       2.9.3 China National Biotec Group Meningococcal Vaccine Product and Services
       2.9.4 China National Biotec Group Meningococcal Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.9.5 China National Biotec Group Recent Developments/Updates
   2.10 Hualan Bio
       2.10.1 Hualan Bio Details
       2.10.2 Hualan Bio Major Business
       2.10.3 Hualan Bio Meningococcal Vaccine Product and Services
       2.10.4 Hualan Bio Meningococcal Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.10.5 Hualan Bio Recent Developments/Updates
   2.11 Walvax
       2.11.1 Walvax Details
       2.11.2 Walvax Major Business
       2.11.3 Walvax Meningococcal Vaccine Product and Services
       2.11.4 Walvax Meningococcal Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.11.5 Walvax Recent Developments/Updates
   2.12 Zhifei
       2.12.1 Zhifei Details
       2.12.2 Zhifei Major Business
       2.12.3 Zhifei Meningococcal Vaccine Product and Services
       2.12.4 Zhifei Meningococcal Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.12.5 Zhifei Recent Developments/Updates

3 Competitive Environment: Meningococcal Vaccine by Manufacturer

   3.1 Global Meningococcal Vaccine Sales Quantity by Manufacturer (2018-2023)
   3.2 Global Meningococcal Vaccine Revenue by Manufacturer (2018-2023)
   3.3 Global Meningococcal Vaccine Average Price by Manufacturer (2018-2023)
   3.4 Market Share Analysis (2022)
       3.4.1 Producer Shipments of Meningococcal Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2022
       3.4.2 Top 3 Meningococcal Vaccine Manufacturer Market Share in 2022
       3.4.2 Top 6 Meningococcal Vaccine Manufacturer Market Share in 2022
   3.5 Meningococcal Vaccine Market: Overall Company Footprint Analysis
       3.5.1 Meningococcal Vaccine Market: Region Footprint
       3.5.2 Meningococcal Vaccine Market: Company Product Type Footprint
       3.5.3 Meningococcal Vaccine Market: Company Product Application Footprint
   3.6 New Market Entrants and Barriers to Market Entry
   3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

   4.1 Global Meningococcal Vaccine Market Size by Region
       4.1.1 Global Meningococcal Vaccine Sales Quantity by Region (2018-2029)
       4.1.2 Global Meningococcal Vaccine Consumption Value by Region (2018-2029)
       4.1.3 Global Meningococcal Vaccine Average Price by Region (2018-2029)
   4.2 North America Meningococcal Vaccine Consumption Value (2018-2029)
   4.3 Europe Meningococcal Vaccine Consumption Value (2018-2029)
   4.4 Asia-Pacific Meningococcal Vaccine Consumption Value (2018-2029)
   4.5 South America Meningococcal Vaccine Consumption Value (2018-2029)
   4.6 Middle East and Africa Meningococcal Vaccine Consumption Value (2018-2029)

5 Market Segment by Type

   5.1 Global Meningococcal Vaccine Sales Quantity by Type (2018-2029)
   5.2 Global Meningococcal Vaccine Consumption Value by Type (2018-2029)
   5.3 Global Meningococcal Vaccine Average Price by Type (2018-2029)

6 Market Segment by Application

   6.1 Global Meningococcal Vaccine Sales Quantity by Application (2018-2029)
   6.2 Global Meningococcal Vaccine Consumption Value by Application (2018-2029)
   6.3 Global Meningococcal Vaccine Average Price by Application (2018-2029)

7 North America

   7.1 North America Meningococcal Vaccine Sales Quantity by Type (2018-2029)
   7.2 North America Meningococcal Vaccine Sales Quantity by Application (2018-2029)
   7.3 North America Meningococcal Vaccine Market Size by Country
       7.3.1 North America Meningococcal Vaccine Sales Quantity by Country (2018-2029)
       7.3.2 North America Meningococcal Vaccine Consumption Value by Country (2018-2029)
       7.3.3 United States Market Size and Forecast (2018-2029)
       7.3.4 Canada Market Size and Forecast (2018-2029)
       7.3.5 Mexico Market Size and Forecast (2018-2029)

8 Europe

   8.1 Europe Meningococcal Vaccine Sales Quantity by Type (2018-2029)
   8.2 Europe Meningococcal Vaccine Sales Quantity by Application (2018-2029)
   8.3 Europe Meningococcal Vaccine Market Size by Country
       8.3.1 Europe Meningococcal Vaccine Sales Quantity by Country (2018-2029)
       8.3.2 Europe Meningococcal Vaccine Consumption Value by Country (2018-2029)
       8.3.3 Germany Market Size and Forecast (2018-2029)
       8.3.4 France Market Size and Forecast (2018-2029)
       8.3.5 United Kingdom Market Size and Forecast (2018-2029)
       8.3.6 Russia Market Size and Forecast (2018-2029)
       8.3.7 Italy Market Size and Forecast (2018-2029)

9 Asia-Pacific

   9.1 Asia-Pacific Meningococcal Vaccine Sales Quantity by Type (2018-2029)
   9.2 Asia-Pacific Meningococcal Vaccine Sales Quantity by Application (2018-2029)
   9.3 Asia-Pacific Meningococcal Vaccine Market Size by Region
       9.3.1 Asia-Pacific Meningococcal Vaccine Sales Quantity by Region (2018-2029)
       9.3.2 Asia-Pacific Meningococcal Vaccine Consumption Value by Region (2018-2029)
       9.3.3 China Market Size and Forecast (2018-2029)
       9.3.4 Japan Market Size and Forecast (2018-2029)
       9.3.5 Korea Market Size and Forecast (2018-2029)
       9.3.6 India Market Size and Forecast (2018-2029)
       9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
       9.3.8 Australia Market Size and Forecast (2018-2029)

10 South America

   10.1 South America Meningococcal Vaccine Sales Quantity by Type (2018-2029)
   10.2 South America Meningococcal Vaccine Sales Quantity by Application (2018-2029)
   10.3 South America Meningococcal Vaccine Market Size by Country
       10.3.1 South America Meningococcal Vaccine Sales Quantity by Country (2018-2029)
       10.3.2 South America Meningococcal Vaccine Consumption Value by Country (2018-2029)
       10.3.3 Brazil Market Size and Forecast (2018-2029)
       10.3.4 Argentina Market Size and Forecast (2018-2029)

11 Middle East & Africa

   11.1 Middle East & Africa Meningococcal Vaccine Sales Quantity by Type (2018-2029)
   11.2 Middle East & Africa Meningococcal Vaccine Sales Quantity by Application (2018-2029)
   11.3 Middle East & Africa Meningococcal Vaccine Market Size by Country
       11.3.1 Middle East & Africa Meningococcal Vaccine Sales Quantity by Country (2018-2029)
       11.3.2 Middle East & Africa Meningococcal Vaccine Consumption Value by Country (2018-2029)
       11.3.3 Turkey Market Size and Forecast (2018-2029)
       11.3.4 Egypt Market Size and Forecast (2018-2029)
       11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
       11.3.6 South Africa Market Size and Forecast (2018-2029)

12 Market Dynamics

   12.1 Meningococcal Vaccine Market Drivers
   12.2 Meningococcal Vaccine Market Restraints
   12.3 Meningococcal Vaccine Trends Analysis
   12.4 Porters Five Forces Analysis
       12.4.1 Threat of New Entrants
       12.4.2 Bargaining Power of Suppliers
       12.4.3 Bargaining Power of Buyers
       12.4.4 Threat of Substitutes
       12.4.5 Competitive Rivalry
   12.5 Influence of COVID-19 and Russia-Ukraine War
       12.5.1 Influence of COVID-19
       12.5.2 Influence of Russia-Ukraine War

13 Raw Material and Industry Chain

   13.1 Raw Material of Meningococcal Vaccine and Key Manufacturers
   13.2 Manufacturing Costs Percentage of Meningococcal Vaccine
   13.3 Meningococcal Vaccine Production Process
   13.4 Meningococcal Vaccine Industrial Chain

14 Shipments by Distribution Channel

   14.1 Sales Channel
       14.1.1 Direct to End-User
       14.1.2 Distributors
   14.2 Meningococcal Vaccine Typical Distributors
   14.3 Meningococcal Vaccine Typical Customers

15 Research Findings and Conclusion

16 Appendix

   16.1 Methodology
   16.2 Research Process and Data Source
   16.3 Disclaimer

List of Tables

   Table 1. Global Meningococcal Vaccine Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
   Table 2. Global Meningococcal Vaccine Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
   Table 3. Novartis Basic Information, Manufacturing Base and Competitors
   Table 4. Novartis Major Business
   Table 5. Novartis Meningococcal Vaccine Product and Services
   Table 6. Novartis Meningococcal Vaccine Sales Quantity (10K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 7. Novartis Recent Developments/Updates
   Table 8. GSK Basic Information, Manufacturing Base and Competitors
   Table 9. GSK Major Business
   Table 10. GSK Meningococcal Vaccine Product and Services
   Table 11. GSK Meningococcal Vaccine Sales Quantity (10K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 12. GSK Recent Developments/Updates
   Table 13. Merck Basic Information, Manufacturing Base and Competitors
   Table 14. Merck Major Business
   Table 15. Merck Meningococcal Vaccine Product and Services
   Table 16. Merck Meningococcal Vaccine Sales Quantity (10K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 17. Merck Recent Developments/Updates
   Table 18. CSL Basic Information, Manufacturing Base and Competitors
   Table 19. CSL Major Business
   Table 20. CSL Meningococcal Vaccine Product and Services
   Table 21. CSL Meningococcal Vaccine Sales Quantity (10K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 22. CSL Recent Developments/Updates
   Table 23. Baxter Basic Information, Manufacturing Base and Competitors
   Table 24. Baxter Major Business
   Table 25. Baxter Meningococcal Vaccine Product and Services
   Table 26. Baxter Meningococcal Vaccine Sales Quantity (10K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 27. Baxter Recent Developments/Updates
   Table 28. JN International Medical Corporation Basic Information, Manufacturing Base and Competitors
   Table 29. JN International Medical Corporation Major Business
   Table 30. JN International Medical Corporation Meningococcal Vaccine Product and Services
   Table 31. JN International Medical Corporation Meningococcal Vaccine Sales Quantity (10K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 32. JN International Medical Corporation Recent Developments/Updates
   Table 33. Serum Institute of India Basic Information, Manufacturing Base and Competitors
   Table 34. Serum Institute of India Major Business
   Table 35. Serum Institute of India Meningococcal Vaccine Product and Services
   Table 36. Serum Institute of India Meningococcal Vaccine Sales Quantity (10K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 37. Serum Institute of India Recent Developments/Updates
   Table 38. Bio-Med Basic Information, Manufacturing Base and Competitors
   Table 39. Bio-Med Major Business
   Table 40. Bio-Med Meningococcal Vaccine Product and Services
   Table 41. Bio-Med Meningococcal Vaccine Sales Quantity (10K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 42. Bio-Med Recent Developments/Updates
   Table 43. China National Biotec Group Basic Information, Manufacturing Base and Competitors
   Table 44. China National Biotec Group Major Business
   Table 45. China National Biotec Group Meningococcal Vaccine Product and Services
   Table 46. China National Biotec Group Meningococcal Vaccine Sales Quantity (10K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 47. China National Biotec Group Recent Developments/Updates
   Table 48. Hualan Bio Basic Information, Manufacturing Base and Competitors
   Table 49. Hualan Bio Major Business
   Table 50. Hualan Bio Meningococcal Vaccine Product and Services
   Table 51. Hualan Bio Meningococcal Vaccine Sales Quantity (10K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 52. Hualan Bio Recent Developments/Updates
   Table 53. Walvax Basic Information, Manufacturing Base and Competitors
   Table 54. Walvax Major Business
   Table 55. Walvax Meningococcal Vaccine Product and Services
   Table 56. Walvax Meningococcal Vaccine Sales Quantity (10K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 57. Walvax Recent Developments/Updates
   Table 58. Zhifei Basic Information, Manufacturing Base and Competitors
   Table 59. Zhifei Major Business
   Table 60. Zhifei Meningococcal Vaccine Product and Services
   Table 61. Zhifei Meningococcal Vaccine Sales Quantity (10K Pcs), Average Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 62. Zhifei Recent Developments/Updates
   Table 63. Global Meningococcal Vaccine Sales Quantity by Manufacturer (2018-2023) & (10K Pcs)
   Table 64. Global Meningococcal Vaccine Revenue by Manufacturer (2018-2023) & (USD Million)
   Table 65. Global Meningococcal Vaccine Average Price by Manufacturer (2018-2023) & (USD/Pcs)
   Table 66. Market Position of Manufacturers in Meningococcal Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
   Table 67. Head Office and Meningococcal Vaccine Production Site of Key Manufacturer
   Table 68. Meningococcal Vaccine Market: Company Product Type Footprint
   Table 69. Meningococcal Vaccine Market: Company Product Application Footprint
   Table 70. Meningococcal Vaccine New Market Entrants and Barriers to Market Entry
   Table 71. Meningococcal Vaccine Mergers, Acquisition, Agreements, and Collaborations
   Table 72. Global Meningococcal Vaccine Sales Quantity by Region (2018-2023) & (10K Pcs)
   Table 73. Global Meningococcal Vaccine Sales Quantity by Region (2024-2029) & (10K Pcs)
   Table 74. Global Meningococcal Vaccine Consumption Value by Region (2018-2023) & (USD Million)
   Table 75. Global Meningococcal Vaccine Consumption Value by Region (2024-2029) & (USD Million)
   Table 76. Global Meningococcal Vaccine Average Price by Region (2018-2023) & (USD/Pcs)
   Table 77. Global Meningococcal Vaccine Average Price by Region (2024-2029) & (USD/Pcs)
   Table 78. Global Meningococcal Vaccine Sales Quantity by Type (2018-2023) & (10K Pcs)
   Table 79. Global Meningococcal Vaccine Sales Quantity by Type (2024-2029) & (10K Pcs)
   Table 80. Global Meningococcal Vaccine Consumption Value by Type (2018-2023) & (USD Million)
   Table 81. Global Meningococcal Vaccine Consumption Value by Type (2024-2029) & (USD Million)
   Table 82. Global Meningococcal Vaccine Average Price by Type (2018-2023) & (USD/Pcs)
   Table 83. Global Meningococcal Vaccine Average Price by Type (2024-2029) & (USD/Pcs)
   Table 84. Global Meningococcal Vaccine Sales Quantity by Application (2018-2023) & (10K Pcs)
   Table 85. Global Meningococcal Vaccine Sales Quantity by Application (2024-2029) & (10K Pcs)
   Table 86. Global Meningococcal Vaccine Consumption Value by Application (2018-2023) & (USD Million)
   Table 87. Global Meningococcal Vaccine Consumption Value by Application (2024-2029) & (USD Million)
   Table 88. Global Meningococcal Vaccine Average Price by Application (2018-2023) & (USD/Pcs)
   Table 89. Global Meningococcal Vaccine Average Price by Application (2024-2029) & (USD/Pcs)
   Table 90. North America Meningococcal Vaccine Sales Quantity by Type (2018-2023) & (10K Pcs)
   Table 91. North America Meningococcal Vaccine Sales Quantity by Type (2024-2029) & (10K Pcs)
   Table 92. North America Meningococcal Vaccine Sales Quantity by Application (2018-2023) & (10K Pcs)
   Table 93. North America Meningococcal Vaccine Sales Quantity by Application (2024-2029) & (10K Pcs)
   Table 94. North America Meningococcal Vaccine Sales Quantity by Country (2018-2023) & (10K Pcs)
   Table 95. North America Meningococcal Vaccine Sales Quantity by Country (2024-2029) & (10K Pcs)
   Table 96. North America Meningococcal Vaccine Consumption Value by Country (2018-2023) & (USD Million)
   Table 97. North America Meningococcal Vaccine Consumption Value by Country (2024-2029) & (USD Million)
   Table 98. Europe Meningococcal Vaccine Sales Quantity by Type (2018-2023) & (10K Pcs)
   Table 99. Europe Meningococcal Vaccine Sales Quantity by Type (2024-2029) & (10K Pcs)
   Table 100. Europe Meningococcal Vaccine Sales Quantity by Application (2018-2023) & (10K Pcs)
   Table 101. Europe Meningococcal Vaccine Sales Quantity by Application (2024-2029) & (10K Pcs)
   Table 102. Europe Meningococcal Vaccine Sales Quantity by Country (2018-2023) & (10K Pcs)
   Table 103. Europe Meningococcal Vaccine Sales Quantity by Country (2024-2029) & (10K Pcs)
   Table 104. Europe Meningococcal Vaccine Consumption Value by Country (2018-2023) & (USD Million)
   Table 105. Europe Meningococcal Vaccine Consumption Value by Country (2024-2029) & (USD Million)
   Table 106. Asia-Pacific Meningococcal Vaccine Sales Quantity by Type (2018-2023) & (10K Pcs)
   Table 107. Asia-Pacific Meningococcal Vaccine Sales Quantity by Type (2024-2029) & (10K Pcs)
   Table 108. Asia-Pacific Meningococcal Vaccine Sales Quantity by Application (2018-2023) & (10K Pcs)
   Table 109. Asia-Pacific Meningococcal Vaccine Sales Quantity by Application (2024-2029) & (10K Pcs)
   Table 110. Asia-Pacific Meningococcal Vaccine Sales Quantity by Region (2018-2023) & (10K Pcs)
   Table 111. Asia-Pacific Meningococcal Vaccine Sales Quantity by Region (2024-2029) & (10K Pcs)
   Table 112. Asia-Pacific Meningococcal Vaccine Consumption Value by Region (2018-2023) & (USD Million)
   Table 113. Asia-Pacific Meningococcal Vaccine Consumption Value by Region (2024-2029) & (USD Million)
   Table 114. South America Meningococcal Vaccine Sales Quantity by Type (2018-2023) & (10K Pcs)
   Table 115. South America Meningococcal Vaccine Sales Quantity by Type (2024-2029) & (10K Pcs)
   Table 116. South America Meningococcal Vaccine Sales Quantity by Application (2018-2023) & (10K Pcs)
   Table 117. South America Meningococcal Vaccine Sales Quantity by Application (2024-2029) & (10K Pcs)
   Table 118. South America Meningococcal Vaccine Sales Quantity by Country (2018-2023) & (10K Pcs)
   Table 119. South America Meningococcal Vaccine Sales Quantity by Country (2024-2029) & (10K Pcs)
   Table 120. South America Meningococcal Vaccine Consumption Value by Country (2018-2023) & (USD Million)
   Table 121. South America Meningococcal Vaccine Consumption Value by Country (2024-2029) & (USD Million)
   Table 122. Middle East & Africa Meningococcal Vaccine Sales Quantity by Type (2018-2023) & (10K Pcs)
   Table 123. Middle East & Africa Meningococcal Vaccine Sales Quantity by Type (2024-2029) & (10K Pcs)
   Table 124. Middle East & Africa Meningococcal Vaccine Sales Quantity by Application (2018-2023) & (10K Pcs)
   Table 125. Middle East & Africa Meningococcal Vaccine Sales Quantity by Application (2024-2029) & (10K Pcs)
   Table 126. Middle East & Africa Meningococcal Vaccine Sales Quantity by Region (2018-2023) & (10K Pcs)
   Table 127. Middle East & Africa Meningococcal Vaccine Sales Quantity by Region (2024-2029) & (10K Pcs)
   Table 128. Middle East & Africa Meningococcal Vaccine Consumption Value by Region (2018-2023) & (USD Million)
   Table 129. Middle East & Africa Meningococcal Vaccine Consumption Value by Region (2024-2029) & (USD Million)
   Table 130. Meningococcal Vaccine Raw Material
   Table 131. Key Manufacturers of Meningococcal Vaccine Raw Materials
   Table 132. Meningococcal Vaccine Typical Distributors
   Table 133. Meningococcal Vaccine Typical Customers

List of Figures

   Figure 1. Meningococcal Vaccine Picture
   Figure 2. Global Meningococcal Vaccine Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
   Figure 3. Global Meningococcal Vaccine Consumption Value Market Share by Type in 2022
   Figure 4. Meningtits A Examples
   Figure 5. Polysaccharide Meningtitis AC Examples
   Figure 6. Meningitis ACYW Examples
   Figure 7. Global Meningococcal Vaccine Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
   Figure 8. Global Meningococcal Vaccine Consumption Value Market Share by Application in 2022
   Figure 9. 6 Months-15Year Examples
   Figure 10. over 3 Year Examples
   Figure 11. over 2 Year Examples
   Figure 12. over 3 Months Examples
   Figure 13. Global Meningococcal Vaccine Consumption Value, (USD Million): 2018 & 2022 & 2029
   Figure 14. Global Meningococcal Vaccine Consumption Value and Forecast (2018-2029) & (USD Million)
   Figure 15. Global Meningococcal Vaccine Sales Quantity (2018-2029) & (10K Pcs)
   Figure 16. Global Meningococcal Vaccine Average Price (2018-2029) & (USD/Pcs)
   Figure 17. Global Meningococcal Vaccine Sales Quantity Market Share by Manufacturer in 2022
   Figure 18. Global Meningococcal Vaccine Consumption Value Market Share by Manufacturer in 2022
   Figure 19. Producer Shipments of Meningococcal Vaccine by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
   Figure 20. Top 3 Meningococcal Vaccine Manufacturer (Consumption Value) Market Share in 2022
   Figure 21. Top 6 Meningococcal Vaccine Manufacturer (Consumption Value) Market Share in 2022
   Figure 22. Global Meningococcal Vaccine Sales Quantity Market Share by Region (2018-2029)
   Figure 23. Global Meningococcal Vaccine Consumption Value Market Share by Region (2018-2029)
   Figure 24. North America Meningococcal Vaccine Consumption Value (2018-2029) & (USD Million)
   Figure 25. Europe Meningococcal Vaccine Consumption Value (2018-2029) & (USD Million)
   Figure 26. Asia-Pacific Meningococcal Vaccine Consumption Value (2018-2029) & (USD Million)
   Figure 27. South America Meningococcal Vaccine Consumption Value (2018-2029) & (USD Million)
   Figure 28. Middle East & Africa Meningococcal Vaccine Consumption Value (2018-2029) & (USD Million)
   Figure 29. Global Meningococcal Vaccine Sales Quantity Market Share by Type (2018-2029)
   Figure 30. Global Meningococcal Vaccine Consumption Value Market Share by Type (2018-2029)
   Figure 31. Global Meningococcal Vaccine Average Price by Type (2018-2029) & (USD/Pcs)
   Figure 32. Global Meningococcal Vaccine Sales Quantity Market Share by Application (2018-2029)
   Figure 33. Global Meningococcal Vaccine Consumption Value Market Share by Application (2018-2029)
   Figure 34. Global Meningococcal Vaccine Average Price by Application (2018-2029) & (USD/Pcs)
   Figure 35. North America Meningococcal Vaccine Sales Quantity Market Share by Type (2018-2029)
   Figure 36. North America Meningococcal Vaccine Sales Quantity Market Share by Application (2018-2029)
   Figure 37. North America Meningococcal Vaccine Sales Quantity Market Share by Country (2018-2029)
   Figure 38. North America Meningococcal Vaccine Consumption Value Market Share by Country (2018-2029)
   Figure 39. United States Meningococcal Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 40. Canada Meningococcal Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 41. Mexico Meningococcal Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 42. Europe Meningococcal Vaccine Sales Quantity Market Share by Type (2018-2029)
   Figure 43. Europe Meningococcal Vaccine Sales Quantity Market Share by Application (2018-2029)
   Figure 44. Europe Meningococcal Vaccine Sales Quantity Market Share by Country (2018-2029)
   Figure 45. Europe Meningococcal Vaccine Consumption Value Market Share by Country (2018-2029)
   Figure 46. Germany Meningococcal Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 47. France Meningococcal Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 48. United Kingdom Meningococcal Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 49. Russia Meningococcal Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 50. Italy Meningococcal Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 51. Asia-Pacific Meningococcal Vaccine Sales Quantity Market Share by Type (2018-2029)
   Figure 52. Asia-Pacific Meningococcal Vaccine Sales Quantity Market Share by Application (2018-2029)
   Figure 53. Asia-Pacific Meningococcal Vaccine Sales Quantity Market Share by Region (2018-2029)
   Figure 54. Asia-Pacific Meningococcal Vaccine Consumption Value Market Share by Region (2018-2029)
   Figure 55. China Meningococcal Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 56. Japan Meningococcal Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 57. Korea Meningococcal Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 58. India Meningococcal Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 59. Southeast Asia Meningococcal Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 60. Australia Meningococcal Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 61. South America Meningococcal Vaccine Sales Quantity Market Share by Type (2018-2029)
   Figure 62. South America Meningococcal Vaccine Sales Quantity Market Share by Application (2018-2029)
   Figure 63. South America Meningococcal Vaccine Sales Quantity Market Share by Country (2018-2029)
   Figure 64. South America Meningococcal Vaccine Consumption Value Market Share by Country (2018-2029)
   Figure 65. Brazil Meningococcal Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 66. Argentina Meningococcal Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 67. Middle East & Africa Meningococcal Vaccine Sales Quantity Market Share by Type (2018-2029)
   Figure 68. Middle East & Africa Meningococcal Vaccine Sales Quantity Market Share by Application (2018-2029)
   Figure 69. Middle East & Africa Meningococcal Vaccine Sales Quantity Market Share by Region (2018-2029)
   Figure 70. Middle East & Africa Meningococcal Vaccine Consumption Value Market Share by Region (2018-2029)
   Figure 71. Turkey Meningococcal Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 72. Egypt Meningococcal Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 73. Saudi Arabia Meningococcal Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 74. South Africa Meningococcal Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 75. Meningococcal Vaccine Market Drivers
   Figure 76. Meningococcal Vaccine Market Restraints
   Figure 77. Meningococcal Vaccine Market Trends
   Figure 78. Porters Five Forces Analysis
   Figure 79. Manufacturing Cost Structure Analysis of Meningococcal Vaccine in 2022
   Figure 80. Manufacturing Process Analysis of Meningococcal Vaccine
   Figure 81. Meningococcal Vaccine Industrial Chain
   Figure 82. Sales Quantity Channel: Direct to End-User vs Distributors
   Figure 83. Direct Channel Pros & Cons
   Figure 84. Indirect Channel Pros & Cons
   Figure 85. Methodology
   Figure 86. Research Process and Data Source